Letter: corticosteroid use alongside tofacitinib in OCTAVE Open. Authors' reply
暂无分享,去创建一个
B. Sands | J. Lindsay | G. Chan | J. Marshall | W. Sandborn | S. Danese | J. Panés | A. Armuzzi | B. Bressler | J. Colombel | A. Marren | C. Su | N. Lawendy | Haiying Zhang | L. Salese | E. Maller | Konstantinos Tsilkos
[1] Y. An,et al. Letter: the relationship between Helicobacter pylori and coronary heart disease , 2020, Alimentary Pharmacology and Therapeutics.
[2] Chen Peng,et al. Letter: corticosteroid use alongside tofacitinib in OCTAVE Open , 2020, Alimentary pharmacology & therapeutics.
[3] A. Thorpe,et al. DOP61 Tofacitinib, an oral, small-molecule Janus kinase inhibitor, in the treatment of ulcerative colitis: Analysis of an open-label, long-term extension study with up to 5.9 years of treatment , 2020 .
[4] B. Sands,et al. Efficacy and safety of tofacitinib dose de‐escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open , 2019, Alimentary pharmacology & therapeutics.
[5] G. Chan,et al. 706 Impact of Baseline Corticosteroid Therapy on Tofacitinib Induction Efficacy and Infection Risk in Patients With Ulcerative Colitis: Data From Global Clinical Trials , 2019, American Journal of Gastroenterology.
[6] C. Brensinger,et al. Increased Mortality Rates With Prolonged Corticosteroid Therapy When Compared With Antitumor Necrosis Factor-α-Directed Therapy for Inflammatory Bowel Disease , 2018, The American Journal of Gastroenterology.
[7] S. Vermeire,et al. Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis , 2017, The New England journal of medicine.
[8] S. Saini,et al. Corticosteroid Use and Complications in a US Inflammatory Bowel Disease Cohort , 2016, PloS one.